Constellation Pharmaceuticals is a biotechnology business based in the US. Constellation Pharmaceuticals shares (CNST) are listed on the NASDAQ and all prices are listed in US Dollars. Constellation Pharmaceuticals employs 154 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Constellation Pharmaceuticals stock
How to buy Constellation Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CNST. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Constellation Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Constellation Pharmaceuticals stock price (NASDAQ: CNST)
Use our graph to track the performance of CNST stocks over time.Constellation Pharmaceuticals shares at a glance
Latest market close | $19.81 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $33.82 |
200-day moving average | $28.33 |
Wall St. target price | $40.71 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.04 |
Is it a good time to buy Constellation Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Constellation Pharmaceuticals price performance over time
Historical closes compared with the close of $19.81 from 2021-05-28
1 week (2024-08-25) | N/A |
---|---|
1 month (2024-08-01) | N/A |
3 months (2024-06-01) | N/A |
6 months (2024-03-01) | N/A |
1 year (2023-09-01) | N/A |
---|---|
2 years (2022-09-01) | N/A |
3 years (2021-09-01) | N/A |
5 years (2019-09-05) | 174.76% |
Constellation Pharmaceuticals financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -22.41% |
Return on equity TTM | -40.7% |
Profit margin | 0% |
Book value | $7.88 |
Market Capitalization | $1.6 billion |
TTM: trailing 12 months
Constellation Pharmaceuticals share dividends
We're not expecting Constellation Pharmaceuticals to pay a dividend over the next 12 months.
Constellation Pharmaceuticals share price volatility
Over the last 12 months, Constellation Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Constellation Pharmaceuticals's is 2.5804. This would suggest that Constellation Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Constellation Pharmaceuticals overview
Constellation Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008.
Frequently asked questions
nullWhat percentage of Constellation Pharmaceuticals is owned by insiders or institutions?
Currently 1.528% of Constellation Pharmaceuticals shares are held by insiders and 109.699% by institutions. How many people work for Constellation Pharmaceuticals?
Latest data suggests 154 work at Constellation Pharmaceuticals. When does the fiscal year end for Constellation Pharmaceuticals?
Constellation Pharmaceuticals's fiscal year ends in December. Where is Constellation Pharmaceuticals based?
Constellation Pharmaceuticals's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Constellation Pharmaceuticals's ISIN number?
Constellation Pharmaceuticals's international securities identification number is: US2103731061 What is Constellation Pharmaceuticals's CUSIP number?
Constellation Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 210373106
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question